Neuroimaging platform for characterisation of metabolic co morbidities in psycho...
Neuroimaging platform for characterisation of metabolic co morbidities in psychotic disorders
The theme of this collaborative project is development and application of neuroimaging and bioinformatics tools to study lipid metabolism as a common pathogenic link between psychotic disorders and its metabolic co-morbidities. Th...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BES-2012-052585
IDENTIFICACION DE RUTAS METABOLICAS EN LA NEURODEGENERACION...
43K€
Cerrado
FAT4BRAIN
Networking for excellence in functional pharmacology to stud...
799K€
Cerrado
HETODEP
Bringing the field of psychiatry forward Unraveling heterog...
100K€
Cerrado
SAF2011-30578
IDENTIFICACION DE RUTAS METABOLICAS EN LA NEURODEGENERACION...
157K€
Cerrado
PTQ-09-02-02148
EXPLORACIÓN DE NUEVAS DIANAS ENFERMEDADES NEURODEGENERATIVAS...
69K€
Cerrado
Información proyecto METSY
Líder del proyecto
TURUN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
6M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The theme of this collaborative project is development and application of neuroimaging and bioinformatics tools to study lipid metabolism as a common pathogenic link between psychotic disorders and its metabolic co-morbidities. The overall objective is to identify, prioritize and evaluate multi-modal blood and neuroimaging markers with diagnostic potential for prediction and monitoring of psychotic disorders and associated metabolic co-morbidities. We aim to (1) optimise a multidisciplinary approach for combining positron emission tomography (PET) and magnetic resonance imaging (MRI) with metabolomics approaches, (2) develop a PET-method for exploring endocannabinoid pathways in early psychosis in longitudinal study setting, and (3) develop combined PET-MRI biomarker methodology for psychiatric disorders by studying neurotransmitter interactions with multiple PET scan and MRI sequences. The balance of two or more neurotransmitter systems may function as a novel biomarker in these disorders. The expected impacts are (1) etiopathogenic understanding, (2) new validated multi-modal markers for early disease detection and monitoring, (3) new tools for the identification of subjects who may benefit from specific treatment (4) discovery of new avenues for disease prevention and therapy, and (5) new tools and processes for applying brain imaging in personalised medicine. The consortium brings together clinicians, researchers and industry partners in the domains of psychiatry, neuroimaging, metabolic research, systems biology and bioinformatics.